Clinical study with cladribine completed

We have succesfully completed phase I study for female patients suffering from relapsing multiple sclerosis.

The aim of the study was to examine the effect of cladribine used in the treatment of relapsing multiple sclerosis on an oral contraceptive containing ethinyl estradiol and levonorgestrel.

Cladribine is a synthetic purine nucleoside that acts as an antineoplastic agent with immunosuppressive effects. Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, which results in resistance to enzymatic degradation by adenosine deaminase.

Go back

News

Happy Easter!

To all our employees, co-workers, clients and patients we would like to express our best wishes of joyful and peaceful Easter.

Read more …

Pediatrics Clinical Trials - conference

On 16th of April, 2019 we attended an interesting conference concerning clinical trials in pediatrics organised by GCPpl society.

Read more …

Personal Data Security in Clinical Trials

On 21st of March, 2019 our representatives attended workshops concerning personal data security in clinical trials.

Read more …

GCLP accreditation

We are proud to announce that on February 2019 we have received a GCLP certificate which confirms our high quality of services.

Read more …

Christmas wishes

To all our Sponsors, Vendors, Employees and Co-Workers we wish joy and happiness for the in-coming Christmas!

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲